Background:Traumatic wound is a great challenging issue to surgeons, because of large in size, heavily contaminated, infected and unscenic. Infection proceeded to progressive tissue necrosis, septicemia, organ failure or even death. Majority has polymicrobial infections. Bacteriohage therapy will have revolutionized in the treatment of wound. The present study was planned to evaluate the efficacy of topical bacteriophage therapy on large traumatic wounds in comparison with conventional therapy. Methods:The Study conducted from Sept. 2018 to July 2020. Samples between 12- 60 years was taken into study. Customized bacteriophage applied over the wound after serial debridement in case and conventional dressing in control. Fifty four wounded person met the clinical inclusion criteria; 27 in each group. Wound swab and tissue biopsy was taken for bacterial isolation. Isolated specific phage was applied over the wound on alternate day till the wound become sterile and fit for further definitive management. Results: A significant and rapid improvement was observed in wound healing in cases then control group. Average number of day required for complete granulation of wound and attaining sterility was half in cases then control. The hospital stay of the patients on BT was half (20days) than those on CT (40 days). The financial analysis also favours the BT over CT as only 1/third expenditure incurred in BT group as compared to CT Conclusion:Topical Bacteriophage therapy is efficient, effective to clearing the infection in shorter length of time and cost effective for infected traumatic wounds as compared to conventional dressing.
Indian State-Level disease burden initiative road injury collaboration. Mortality due to road injury in India, Lancet Public health. 2020; 5[2] e86-e98.
2.
WHO-Global Status report on road safety2018, Geneva.
3.
PrevaldiCPaolilloCLocatelliC, et al.Management of traumatic wounds in the emergency department: position paper from the academy of emergency medicine and care [AcEMC] and the world society of emergency surgery [WSES]. World J Emerg Surg. 2016;11:30. https://doi.org/10.1186/s13017-016-0084-3
4.
Singer AJHollander JEQuinnJV. Evaluation and management of traumatic lacerations. N Engl J Med. 1997;337:1142-1148.
BowlingAStilwellB. The Nurse in family practice: Practice nurses and nurse practitioners in primary health care. Scutari Press; 1988.
7.
MihaiMMHolbanAMGiurcaneanuC, et al.Microbial biofilms: impact on the pathogenesis of periodontitis, cystic fibrosis, chronic wounds and medical device-related infections. Curr. Top. Med. Chem. 2015;15:1552-1576.
8.
GuptaPSinghHSShuklaVKNathGBhartiyaSK. Bacteriophage therapy of ChronicNonhealing wound: clinical study. Int J Low Extrem Wounds. 2019 Jun;18(2):171-175.
9.
PatelDRBhartiyaSKKumarRShuklaVKNathG. Use of customized bacteriophages inthe treatment of chronic nonhealing wounds: a prospective study. Int J Low Extrem Wounds. 2021 March;20(1):37-46.
10.
DaviesD. Understanding biofilm resistance to antibacterial agents. Nat. Rev. Drug Discov. 2003;2(2):114-122.
11.
JamalMAhmadWAndleebS, et al.Bacterial biofilm and associated infections. J. Chin. Med. Assoc. 2018;81(1):7-11.
PaharikAEHorswillAR. The staphylococcal biofilm: adhesins, regulation, and host response. Microbiol. Spectr. 2016;4(2):1-27.
14.
MerabishviliMPirnayJPVerbekenG. ]. quality-controlled smallscaleproduction of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE. 2009;2009(3):e4944. doi: 10.1371/journal.pone.0004944
15.
BasuSAgarwalMBhartiyaSKNathGShuklaVK. An in vivowound model utilizing bacteriophage therapy of pseudomonasaeruginosa biofilms. Ostomy Wound Manage. 2015;61:16-23.
16.
KishorCMishraRRSarafSKKumarMSrivastavAKNathG. Phage therapy of staphylococcal chronicosteomyelitisinexperimental animal model. Indian J Med Res. 2016;143:87-94.
17.
HarperDRHelenaMRTPJamesW,et al.Bacteriophages and biofilms. Antibiotics [Basel]. 2014 Sep;3(3):270-284.
18.
MiedzybrodzkiRBorysowskiJWeber-DabrowskaB, et al.Clinical aspects of phage therapy. Adv. Virus Res. 2012;83:73-121. doi: 10.1016/B978-0-12-394438-2.00003-7
19.
GórskiA.DabrowskaK.MiedzybrodzkiR., et al [2017]. Phages and immunomodulation. Future Microbiol. 12, 905 to 914. doi: 10.2217/fmb-2017-0049
20.
Van BelleghemJDClementFMerabishviliMLavigneRVaneechoutteM. Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages. Sci. Rep. 2017;7:8004. doi: 10.1038/s41598-017-08336-9
21.
KhairullinINPozdeevOKShaimordanovR. Efficiency of using specific bacteriophages in the treatment and prophylaxis of postoperative surgical infections. Kazan Med. J. 2002;83:258-261.
22.
ArchanaAPatelPSKumarRNathG. Neutralizing antibody response against subcutaneously injected bacteriophages in rabbit model. Virus Disease. 2021;32(1):38-45.
